	US 11,944,615 B2
	Combination therapy for treatment of LKB1 deficient cancers
David Peng, Mohegan Lake, NY (US); Kwok-Kin Wong, Arlington, MA (US); and Jiehui Deng, Port Washington, NY (US)
Assigned to New York University, New York, NY (US)
Filed by New York University, New York, NY (US)
Filed on Sep. 3, 2021, as Appl. No. 17/466,776.
Claims priority of provisional application 63/074,147, filed on Sep. 3, 2020.
Prior Publication US 2022/0062260 A1, Mar. 3, 2022
Int. Cl. A61K 31/4545 (2006.01); A61K 31/497 (2006.01); A61K 31/505 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/4545 (2013.01) [A61K 31/497 (2013.01); A61K 31/505 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)]

13 Claims

1. A method for treatment of cancer, wherein the cancer cells are LKB1 deficient, the method comprising administering to an individual in need of treatment a therapeutically effective amount of a combination of one more CD38 inhibitor selected from the group consisting of daratumumab, isatuximab, CAR-Ts against CD38, GBR 1342, TAK-079, TAK-169, 78c, and apigenin, and immune based therapy to thereby treat the cancer.